These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17624049)

  • 1. Thalidomide in combination with dexamethasone-induced rhabdomyolysis in a patient with refractory myeloma.
    Boga C; Ozdogu H; Yeral M; Kizilkilic E; Tamer L
    J Support Oncol; 2007 Jun; 5(6):256. PubMed ID: 17624049
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.
    Huston A; Brown J; Roodman GD
    Exp Hematol; 2006 Dec; 34(12):1616. PubMed ID: 17157156
    [No Abstract]   [Full Text] [Related]  

  • 3. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
    Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J
    Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
    Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J
    Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Completely reversible agranulocytosis in a multiple myeloma patient treated with thalidomide-dexamethasone.
    Magalini F; Stella A; Sansoni P
    Intern Emerg Med; 2008 Dec; 3(4):383-5. PubMed ID: 18320148
    [No Abstract]   [Full Text] [Related]  

  • 6. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma.
    Rajkumar SV; Gertz MA; Witzig TE
    N Engl J Med; 2000 Sep; 343(13):972-3. PubMed ID: 11012329
    [No Abstract]   [Full Text] [Related]  

  • 7. Fatal sepsis after thalidomide/dexamethasone treatment in two patients with multiple myeloma.
    Wölfler A; Bauer F; Zollner G; Weber K; Sill H; Linkesch W
    Haematologica; 2003 Apr; 88(4):ELT12. PubMed ID: 12681989
    [No Abstract]   [Full Text] [Related]  

  • 8. Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eight patients previously treated with multiple myeloma.
    Bemardeschi P; Dentico P; Rossi S; Fiorentini G; Giustarini G; Turano E
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):129-33. PubMed ID: 16767919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatment option emerges for newly diagnosed multiple myeloma.
    Rollins G
    Rep Med Guidel Outcomes Res; 2002 Nov; 13(23):10, 12. PubMed ID: 12731484
    [No Abstract]   [Full Text] [Related]  

  • 10. Thalidomide in multiple myeloma: state of art.
    Tosi P; Cavo M
    Haematologica; 2002 Mar; 87(3):233-4. PubMed ID: 11869932
    [No Abstract]   [Full Text] [Related]  

  • 11. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
    Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide and venous thrombosis in multiple myeloma.
    Rajkumar SV; Blood E
    N Engl J Med; 2006 May; 354(19):2079-80. PubMed ID: 16696148
    [No Abstract]   [Full Text] [Related]  

  • 14. Thalidomide and thrombosis. A meta-analysis.
    El Accaoui RN; Shamseddeen WA; Taher AT
    Thromb Haemost; 2007 Jun; 97(6):1031-6. PubMed ID: 17549307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
    Ciolli S; Leoni F; Casini C; Breschi C; Santini V; Bosi A
    Br J Haematol; 2008 Jun; 141(6):814-9. PubMed ID: 18410447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma.
    Murakami H; Handa H; Abe M; Iida S; Ishii A; Ishikawa T; Ishida T; Oota M; Ozaki S; Kosaka M; Sakai A; Sawamura M; Shimazaki C; Shimizu K; Takagi T; Hata H; Fukuhara T; Fujii H; Miyata A; Wakayama T; Takatsuki K
    Eur J Haematol; 2007 Sep; 79(3):234-9. PubMed ID: 17655699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
    Palumbo A; Dimopoulos M; San Miguel J; Harousseau JL; Attal M; Hussein M; Knop S; Ludwig H; von Lilienfeld-Toal M; Sonneveld P
    Blood Rev; 2009 Mar; 23(2):87-93. PubMed ID: 18774632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide-based treatment for HIV-associated multiple myeloma: a case report.
    Aboulafia DM
    AIDS Read; 2003 Aug; 13(8):383-9. PubMed ID: 14524324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Deep vein thrombosis and pulmonary embolism in a patient with multiple myeloma treated with thalidomide and dexamethasone].
    Miyazawa Y; Irisawa H; Uchiumi H; Saitoh T; Handa H; Matsushima T; Tsukamoto N; Karasawa M; Murakami H; Nojima Y
    Rinsho Ketsueki; 2006 Jul; 47(7):656-60. PubMed ID: 16910577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advantages of using thalidomide for the management of refractory myeloma patients.
    Corso A; Lorenzi A; Orlandi E; Astori C; Mangiacavalli S; Lazzarino M
    Haematologica; 2002 Mar; 87(3):327-8. PubMed ID: 11869949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.